




# Cirrhosis Prediction

By Ashik Sathiya

# Context

# The Problem

- Cirrhosis is advanced liver scarring caused by various liver diseases like hepatitis and chronic alcoholism.
- **Goal:** Predict what stage of Cirrhosis a patient is in based on patient data in order to create better treatment plans and improve patient outcome





# Potential Benefits

- **Early Intervention and Improved Treatment Planning:**
  - Early detection and treatment can slow down or stop progression of cirrhosis, leading to better outcomes for the patients.
- **Tailored Treatment Approach:**
  - Predicting the stage helps doctors create a more tailored treatment plans to the specific needs and severity of the patient's condition,
- **Resource Allocation:**
  - Hospitals can allocate resources more efficiently based Patients with more advanced stages requiring closer monitoring, and specialized care



# Stakeholders

Stakeholders	
<b>Patients with PBC</b>	Individuals diagnosed with primary biliary cirrhosis
<b>Mayo Clinic</b>	Conducting the trial and collecting data, with an interest in improving treatments for PBC
<b>Medical Researchers and Doctors</b>	Professionals involved in designing, conducting, and analyzing the trial
<b>Drug Manufacturers</b>	Companies producing drugs like D-penicillamine, and are interested in effectiveness of drug and market opportunities




# Dataset

- Data is from the Mayo Clinic trial on primary biliary cirrhosis (PBC) conducted from 1974 to 1984
- The trial involved 424 PBC patients eligible for a drug trial on D-penicillamine within a ten-year period
- 312 cases participated in the randomized trial, having comprehensive data.
- 112 cases did not take part in the trial but agreed to have measurements and survival data recorded
- Six cases were lost to follow-up after diagnosis, leaving 106 cases along with the 312 trial participants in the dataset




# Insights



Status: status of the patient C (censored), CL (censored due to liver tx), or D (death)





Cholesterol By Age Grouped by Sex

# Recommendation

# Target

Our Target Value is the 'Stage' column.

- Initially the Value Counts within Stage were a bit Unbalanced
- Merged Stage 0 to Stage 1

3	155
4	144
2	92
1	21
0	6

Before



3	155
4	144
2	92
1	27

After


# Best Performing Model

## KNN Model Tuned After Applying PCA


Classification Metrics: Training Data

	precision	recall	f1-score	support
0	1.00	1.00	1.00	4
1	1.00	1.00	1.00	18
2	1.00	1.00	1.00	76
3	1.00	1.00	1.00	123
4	1.00	1.00	1.00	113
accuracy			1.00	334
macro avg	1.00	1.00	1.00	334
weighted avg	1.00	1.00	1.00	334

Raw Counts




Normalized Confusion Matrix




Classification Metrics: Test Data

	precision	recall	f1-score	support
0	0.00	0.00	0.00	2
1	0.00	0.00	0.00	3
2	0.36	0.25	0.30	16
3	0.43	0.59	0.50	32
4	0.66	0.61	0.63	31
accuracy			0.50	84
macro avg	0.29	0.29	0.29	84
weighted avg	0.48	0.50	0.48	84

Raw Counts



Normalized Confusion Matrix





# Final Recommendation

- Although this is a good start it is clear that sampling of target values is severely affecting model performance.
- Future Steps:
  - Applying Resampling methods (Over or Under Sampling ) May Help Yield Better Results
  - Deep Learning Models
  - Further Feature Engineering